Related references
Note: Only part of the references are listed.Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone Interim report of a longitudinal cohort study
James D. Lewis et al.
DIABETES CARE (2011)
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
Sreenivasa Rao Kondapally Seshasai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Metformin as an antitumor agent in cancer prevention and treatment
Donghui Li
JOURNAL OF DIABETES (2011)
Epidemiological aspects of neoplasms in diabetes
Antonio Nicolucci
ACTA DIABETOLOGICA (2010)
Diabetes and Cancer A consensus report
Edward Giovannucci et al.
DIABETES CARE (2010)
Evaluation of a hepatitis B vaccination program in Taiwan: impact on hepatocellular carcinoma development
Isabelle Chemin
FUTURE ONCOLOGY (2010)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Peroxisome Proliferator-Activated Receptor gamma Pathway Targeting in Carcinogenesis: Implications for Chemoprevention
Frank Ondrey
CLINICAL CANCER RESEARCH (2009)
Thiazolidinediones and heart failure
Parminder S. Chaggar et al.
DIABETES & VASCULAR DISEASE RESEARCH (2009)
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes An Overview of Data from PROactive
John Dormandy et al.
DRUG SAFETY (2009)
CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone
D. John Betteridge
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2009)
Pegylated interferon α-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy
C-H Liu et al.
GUT (2009)
A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish
Beatrice Secretan et al.
LANCET ONCOLOGY (2009)
Important prognostic factors for the long-term survival of lung cancer subjects in Taiwan
Tai-An Chiang et al.
BMC CANCER (2008)
Pegylated Interferon-α-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial
Chen-Hua Liu et al.
CLINICAL INFECTIOUS DISEASES (2008)
Rosiglitazone and risk of cancer - A meta-analysis of randomized clinical trials
Matteo Monami et al.
DIABETES CARE (2008)
Thiazolidinedione Therapy Is Not Associated With Increased Colonic Neoplasia Risk in Patients With Diabetes Mellitus
James D. Lewis et al.
GASTROENTEROLOGY (2008)
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: A follow-up study in Taiwan
Chi-Ling Chen et al.
GASTROENTEROLOGY (2008)
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis
Jing Ma et al.
LANCET ONCOLOGY (2008)
Pegylated interferon α-2a versus standard interferon α-2a for treatment-naive dialysis patients with chronic hepatitis C:: a randomised study
C-H Liu et al.
GUT (2008)
The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases
J. R. Kramer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death
George A. Diamond et al.
ANNALS OF INTERNAL MEDICINE (2007)
Hepatocellular carcinoma in Taiwan
Ding-Shinn Chen
HEPATOLOGY RESEARCH (2007)
Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System
Maria E. Ramos-Nino et al.
BMC MEDICINE (2007)
Cancer risks in thiazolidinedione users compared to other anti-diabetic agents
Carol Koro et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Rangaswamy Govindarajan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Thiazolidinedione anti-cancer activity: Is inhibition of microtubute assembly implicated?
Wade A. Russu
MEDICAL HYPOTHESES (2007)
The burden of diabetes mellitus among US youth: Prevalence estimates from the SEARCH for Diabetes in Youth Study
Angela D. Liese et al.
PEDIATRICS (2006)
1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPARγ-dependent and PPARγ-independent pathways
Sudhakar Chintharlapalli et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Ligand activation of peroxisome proliferator-activated receptor β inhibits colon carcinogenesis
HE Marin et al.
CANCER RESEARCH (2006)
American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention: Reducing the risk of cancer with healthy food choices and physical activity
Lawrence H. Kushi et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2006)
Peroxisome proliferator-activated receptor-γ ligands suppress fibronectin gene expression in human lung carcinoma cells:: involvement of both CRE and Sp1
SW Han et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2005)
PPARγ as a therapeutic target for tumor angiogenesis and metastasis
D Panigrahy et al.
CANCER BIOLOGY & THERAPY (2005)
Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC)
Y Bren-Mattison et al.
ONCOGENE (2005)
Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer
VG Keshamouni et al.
ONCOGENE (2004)
Physical activity and cancer prevention - Data from epidemiologic studies
IM Lee
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE (2003)
Evaluating medication effects outside of clinical trials: New-user designs
WA Ray
AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)
Activation of peroxisome proliferator-activated receptor-γ stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells
T Satoh et al.
ONCOGENE (2002)
Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells
K Ohta et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Share Paper
